|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Nello_Mainolfi
|
|
gptkbp:collaboratedWith
|
gptkb:Vertex_Pharmaceuticals
gptkb:Sanofi
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
drug discovery
protein degradation
therapeutics development
|
|
gptkbp:foundedYear
|
2016
|
|
gptkbp:founder
|
gptkb:Jared_Gollob
gptkb:Mark_E._Rolfe
gptkb:Nello_Mainolfi
gptkb:Stuart_L._Schreiber
|
|
gptkbp:headquartersLocation
|
gptkb:Watertown,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kymera Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
2020
|
|
gptkbp:notableProduct
|
gptkb:KT-333
gptkb:KT-413
gptkb:KT-474
|
|
gptkbp:numberOfEmployees
|
~200 (2023)
|
|
gptkbp:platform
|
gptkb:Targeted_Protein_Degradation
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:KYMR
|
|
gptkbp:therapeuticArea
|
immunology
oncology
inflammation
|
|
gptkbp:website
|
https://www.kymeratx.com/
|
|
gptkbp:bfsParent
|
gptkb:Arsenal_Yards
gptkb:Alexandria_Venture_Investments
gptkb:David_Grayzel
|
|
gptkbp:bfsLayer
|
6
|